Navigation Links
Sunesis to Present at the 11th Annual BIO CEO & Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that the company will be presenting at the upcoming 11th Annual BIO CEO & Investor Conference at 11:30 a.m. Eastern Time on February 10, 2009 at the Waldorf-Astoria Hotel in New York City, NY.

The live webcast of this presentation will be available on the Sunesis website at A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing voreloxin in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
(Date:11/24/2015)... PA (PRWEB) , ... November 24, 2015 , ... This ... entrepreneurs at competitive events in five states to develop and pitch their BIG ideas ... projects from each state are competing for votes to win the title of SAP's ...
(Date:11/24/2015)... , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today ... December 29, 2015 at 11:00 a.m. Israel time, ... Tower, 98 Yigal Allon Street, 36 th Floor, Tel ... Eric Paneth and Izhak Tamir to the Board ... Skaliter as external directors; , approval of an amendment to certain ...
(Date:11/24/2015)... ... ... InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment ... Chief Operating Officer. , Having joined InSphero in November 2013 as Business ... to Head of InSphero Diagnostics in 2014. There she has built up the ...
(Date:11/24/2015)... Va. , Nov. 24, 2015 ... focused on discovering drugs for metabolic disorders, announced ... to its Board of Directors (BOD). Mr. ... officer of Human Genome Sciences (HGS), and also ... Organization. Jim Powers , Chairman and ...
Breaking Biology Technology:
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
Breaking Biology News(10 mins):